Literature DB >> 18068093

From bench to bedside: successful translational nanomedicine: highlights of the Third Annual Meeting of the American Academy of Nanomedicine.

Chiming Wei1, Nanhai Liu, Pingyi Xu, Mike Heller, Donald A Tomalia, Donald T Haynie, Esther H Chang, Kuan Wang, Yoon-Sik Lee, Yuri L Lyubchenko, Raj Bawa, Ryan Tian, Justin Hanes, Suzie Pun, Jens-Christian Meiners, Peixuan Guo.   

Abstract

The Third Annual Meeting of the American Academy of Nanomedicine (AANM) was held at the University of California San Diego, in San Diego, California during September 7-8, 2007. The meeting was focused on successful translational nanomedicine: from bench to bedside. There were four keynote lectures and eight scientific symposiums in this meeting. The researchers and investigators reported the results and process of current nanomedicine research and approaches to clinical applications. The meeting provided exciting information for nanomedicine clinical-related researches and strategy for further development of nanomedicine research which will be benefits to clinical practice.

Mesh:

Year:  2007        PMID: 18068093     DOI: 10.1016/j.nano.2007.10.005

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  4 in total

Review 1.  Nanomedicine in otorhinolaryngology: what does the future hold?

Authors:  Carl M Philpott; Simon Gane; David McKiernan
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-11-27       Impact factor: 2.503

2.  AFM for analysis of structure and dynamics of DNA and protein-DNA complexes.

Authors:  Yuri L Lyubchenko; Luda S Shlyakhtenko
Journal:  Methods       Date:  2008-10-07       Impact factor: 3.608

3.  Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp.

Authors:  Minzhi Zhao; Chunni Lei; Yadong Yang; Xiangli Bu; Huailei Ma; He Gong; Juan Liu; Xiangdong Fang; Zhiyuan Hu; Qiaojun Fang
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

4.  Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1).

Authors:  Minzhi Zhao; Haiyun Li; Yan Ma; He Gong; Shu Yang; Qiaojun Fang; Zhiyuan Hu
Journal:  Int J Nanomedicine       Date:  2017-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.